References
- Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenitoine. Journal of Pharmacology and Biopharmacology 1980; 8: 165–176
- Bruno G. A., Christian J. E. Determination of 14C in aqueous bicarbonate solutions by liquid scintillation counting. Annals of Chemistry 1961; 33: 1216–1218
- Clozel J-P., Fischli W. Comparative effects of three different potent renin inhibitors in primates. Hypertension 1993; 22: 9–17
- Edwards C. R. W., Padfield P. L. Angiotensin-converting enzyme inhibitors: past, present and bright future. Lancet 1985; 1: 30–34
- Erdös E. G. Angiotensin I converting enzyme. Circulation Research 1975; 36: 247–255
- Fischli W., Clozel J-P., El Amrani K., Wostl W., Neidhart W., Stadler H., Branca Q. Ro 42–5892 is a potent orally active renin inhibitor in primates. Hypertension 1991; 18: 22–31
- Harduf Z., Nir T., Juven B. J. High performance liquid chromatography of biogenic amines, denvatized with 9-fluorenylmethyl chloroformate. Journal of Chromatography 1988; 437: 379–386
- Kleinblœsem C. H., Weber C., Fahrner E., Dellenbach M., Welker H., Schröter V., Belz G. G. Hemodynamics, biochemical effects and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clinical Pharmacology and Therapeutics 1993; 53: 585–592
- Kobrin I., Viskoper R. J., Laszt A., Bock J., Weber C., Charlon V. Effects of an orally active renin inhibitor, Ro 42–5892, in patients with essential hypertension. American Journal of Hypertension 1993; 6: 349–356
- Kokubu T., Hiwada K. Human renin inhibitors. Drugs Today 1987; 23: 101–108
- Lindgren B. R., Andersson R. G. G. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. Medical Toxicology and Adverse Drug Experiments 1989; 4: 369–380
- Lutz R. J., Dedrick R. L., Tuey D., Sipes M. W., Anderson H. B., Mathews H. B. Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog and monkey by means of a physiological pharmacokinetic model. Drug Metabolism and Disposition 1984; 12: 527–535
- Ohnhaus E. E., Locher J. T. Liver blood flow and blood volume following chronic phenobarbitone administration. European Journal of Pharmacology 1975; 31: 161–165
- Rongen G. A., Lenders J. W. M., Kleinblœsem C. H., Weber C., Welker H., Fahrner E., Pozenel H., Woittiez A-J. J., Haug G., Buchmann M. S., Höglund C. E. K., Thien T. Efficacy and tolerability of the renin inhibitor Ro 42–5892 in patients with hypertension. Clinical Pharmacology and Therapeutics 1993; 54: 567–577
- Sato T. New method for measurement of hepatic blood flow in the rat using thermodilution method. Circulation Shock 1987; 21: 31–37
- Shah A. J., Adlard M. W. Determination of β-lactams and their biosynthetic intermediates in fermentation media by pre-column derivatisation followed by fluorescence detection. Journal of Chromatography 1988; 424: 325–336
- van den Meiracker A. H., Admirral P. J. J., Man In't Veld A. J., Derkx F. H. M., Van Eck H. J. R., Mulder P., Schalekamp M. A. D.H. Prolonged blood pressure reduction by orally active renin inhibitor Ro 42–5892 in essential hypertension. British Medical Journal 1990; 301: 205–210
- Viskoper R. J., Charlon V., Laszt A., Yosefy C., Bock J., Landau M., Kobrin I. Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42–5892. Journal of Human Hypertension 1994; 8: 133–136
- Waeber B., Nussberger J., Brunner H. R. The renin-angiotensin system: role in experimental and human hypertension. Handbook of Hypertension, W. H. Birkenhaeger, J. L. Reid. elsevier, Amsterdam 1986; 8, 489–519
- Weber C., Birnböck H., Leube J., Kobrin I., Kleinblœsem C. H., van Brummelen P. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42–5892) in hypertensive patients. British Journal of Clinical Pharmacology 1993; 36: 547–554